BR112018005499A2 - métodos de tratamento de pressão intraocular com ativadores de tie-2. - Google Patents
métodos de tratamento de pressão intraocular com ativadores de tie-2.Info
- Publication number
- BR112018005499A2 BR112018005499A2 BR112018005499A BR112018005499A BR112018005499A2 BR 112018005499 A2 BR112018005499 A2 BR 112018005499A2 BR 112018005499 A BR112018005499 A BR 112018005499A BR 112018005499 A BR112018005499 A BR 112018005499A BR 112018005499 A2 BR112018005499 A2 BR 112018005499A2
- Authority
- BR
- Brazil
- Prior art keywords
- activators
- tie
- methods
- intraocular pressure
- treating intraocular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562222481P | 2015-09-23 | 2015-09-23 | |
PCT/US2016/053107 WO2017053566A1 (en) | 2015-09-23 | 2016-09-22 | Methods of treating intraocular pressure with activators of tie-2 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018005499A2 true BR112018005499A2 (pt) | 2018-10-09 |
Family
ID=58276474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018005499A BR112018005499A2 (pt) | 2015-09-23 | 2016-09-22 | métodos de tratamento de pressão intraocular com ativadores de tie-2. |
Country Status (15)
Country | Link |
---|---|
US (3) | US10952992B2 (pt) |
EP (2) | EP3977994B1 (pt) |
JP (2) | JP6959924B2 (pt) |
KR (1) | KR20180054677A (pt) |
CN (2) | CN108290057A (pt) |
AU (2) | AU2016326510B2 (pt) |
BR (1) | BR112018005499A2 (pt) |
CA (1) | CA2998673C (pt) |
ES (1) | ES2894802T3 (pt) |
IL (1) | IL258150B (pt) |
MX (2) | MX2018003542A (pt) |
MY (1) | MY194736A (pt) |
PH (1) | PH12018500658A1 (pt) |
SG (1) | SG10201912000WA (pt) |
WO (1) | WO2017053566A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
PT2451279T (pt) | 2009-07-06 | 2019-06-18 | Aerpio Therapeutics Inc | Derivados de benzosulfonamida, composições dos mesmos, e uso dos mesmos na prevenção de metástases de células cancerígenas |
AU2012323856B2 (en) | 2011-10-13 | 2017-05-25 | EyePoint Pharmaceuticals, Inc. | Methods for treating Vascular Leak Syndrome and cancer |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
JP6959924B2 (ja) * | 2015-09-23 | 2021-11-05 | エアーピオ ファーマシューティカルズ, インコーポレイテッド | Tie−2の活性化物質を用いる眼内圧を処置する方法 |
SG11201900464TA (en) | 2016-07-20 | 2019-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
JP2021530530A (ja) * | 2018-07-13 | 2021-11-11 | スーザン クアギン | 緑内障におけるve−ptp阻害 |
WO2020214851A1 (en) * | 2019-04-18 | 2020-10-22 | Aerpio Pharmaceuticals, Inc. | Methods of treating hypertension with activators of tie-2 |
CA3138682A1 (en) | 2019-04-29 | 2020-11-05 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
US11413242B2 (en) | 2019-06-24 | 2022-08-16 | EyePoint Pharmaceuticals, Inc. | Formulations of Tie-2 activators and methods of use thereof |
US11613534B2 (en) | 2019-10-29 | 2023-03-28 | EyePoint Pharmaceuticals, Inc. | Small molecule activators of Tie-2 |
CN114929216A (zh) * | 2020-01-08 | 2022-08-19 | 视点制药公司 | Tie-2激活剂和***素的组合及其用途 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US645503A (en) | 1899-05-11 | 1900-03-13 | Timothy Francis Crowley | Cutter-gage for ice-cream, & c. |
US953924A (en) | 1909-06-28 | 1910-04-05 | Dow Wire & Iron Works | Sliding door. |
US20030040463A1 (en) | 1996-04-05 | 2003-02-27 | Wiegand Stanley J. | TIE-2 ligands, methods of making and uses thereof |
WO1998018914A1 (en) | 1996-10-31 | 1998-05-07 | Duke University | Soluble tie2 receptor |
US5980929A (en) | 1998-03-13 | 1999-11-09 | Johns Hopkins University, School Of Medicine | Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation |
US5919813C1 (en) | 1998-03-13 | 2002-01-29 | Univ Johns Hopkins Med | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
WO2000057901A1 (en) | 1999-03-26 | 2000-10-05 | Regeneron Pharmaceuticals, Inc. | Modulation of vascular permeability by means of tie2 receptor activators |
US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
EP1046715A1 (en) | 1999-04-23 | 2000-10-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2 |
US6897201B2 (en) * | 2000-08-21 | 2005-05-24 | Inspire Pharmaceuticals, Inc. | Compositions and methods for the treatment of glaucoma or ocular hypertension |
AU2002335085A1 (en) | 2001-10-25 | 2003-05-06 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
AU2003229627A1 (en) | 2002-04-08 | 2003-10-20 | Max-Planck-Gesellschaft Zur | Ve-ptp as regulator of ve-cadherin mediated processes or disorders |
CA2483449A1 (en) | 2002-04-25 | 2003-11-06 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
US8298532B2 (en) | 2004-01-16 | 2012-10-30 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
PL2653465T3 (pl) | 2004-03-15 | 2017-01-31 | Janssen Pharmaceutica Nv | Modulatory receptora opioidowego |
US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
AU2005269716B2 (en) | 2004-07-20 | 2011-01-27 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
EP2457578B1 (en) | 2004-09-28 | 2015-08-19 | Aprogen, Inc. | Chimeric molecule comprising angiopoietin-1 and a coiled-coil domain for use in treating penile erectile dysfunction |
RU2394839C2 (ru) | 2004-12-21 | 2010-07-20 | Астразенека Аб | Антитела против ангиопоэтина-2 и их применение |
US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
US20070154482A1 (en) | 2005-09-12 | 2007-07-05 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
TW200744567A (en) * | 2005-09-23 | 2007-12-16 | Alcon Inc | Phenylethylamine analogs and their use for treating glaucoma |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
NZ569787A (en) | 2005-12-15 | 2011-07-29 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer |
CN104623692A (zh) | 2006-03-08 | 2015-05-20 | 阿切埃米克斯股份有限公司 | 治疗视觉失调中使用的补体结合适体和抗-c5药物 |
MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
DE102006016426A1 (de) * | 2006-04-07 | 2007-10-11 | Merck Patent Gmbh | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren |
US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7622593B2 (en) * | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
CA2693383C (en) | 2006-10-27 | 2017-03-28 | Sunnybrook Health Sciences Center | Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
WO2009105774A2 (en) | 2008-02-21 | 2009-08-27 | Sequoia Pharmaceuticals, Inc. | Amino acid inhibitors of cytochrome p450 |
TR201809280T4 (tr) | 2009-01-12 | 2018-07-23 | Aerpio Therapeutics Inc | Vasküler sızıntı sendromunun tedavi edilmesine yönelik yöntemler. |
AU2011312203C1 (en) | 2009-01-12 | 2016-09-08 | EyePoint Pharmaceuticals, Inc. | Compositions and methods for treating ocular edema, neovascularization and related diseases |
US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
WO2010097800A1 (en) * | 2009-02-26 | 2010-09-02 | Muhammad Abdulrazik | Synergistic combination of bioactive compounds for lowering of intraocular pressure |
BRPI1008920A2 (pt) | 2009-03-03 | 2015-08-25 | Alcon Res Ltd | Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho |
KR20110130454A (ko) | 2009-03-03 | 2011-12-05 | 알콘 리서치, 리미티드 | 리셉터 티로신 키나제 저해(RTKi) 화합물을 눈에 전달하기 위한 약학 조성물 |
US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
PT2451279T (pt) | 2009-07-06 | 2019-06-18 | Aerpio Therapeutics Inc | Derivados de benzosulfonamida, composições dos mesmos, e uso dos mesmos na prevenção de metástases de células cancerígenas |
CA2803675A1 (en) | 2010-07-12 | 2012-01-19 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
US20180092883A1 (en) | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
WO2012073627A1 (ja) | 2010-12-02 | 2012-06-07 | 丸善製薬株式会社 | Tie2活性化剤、血管内皮増殖因子(VEGF)阻害剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物 |
AU2012323856B2 (en) | 2011-10-13 | 2017-05-25 | EyePoint Pharmaceuticals, Inc. | Methods for treating Vascular Leak Syndrome and cancer |
CN104066448A (zh) | 2011-10-13 | 2014-09-24 | 阿尔皮奥治疗学股份有限公司 | 眼病的治疗 |
US20130190324A1 (en) | 2011-12-23 | 2013-07-25 | The Regents Of The University Of Colorado, A Body Corporate | Topical ocular drug delivery |
WO2013155512A2 (en) | 2012-04-13 | 2013-10-17 | The Johns Hopkins University | Treatment of ischemic retinopathies |
KR101774121B1 (ko) | 2012-07-13 | 2017-09-01 | 로슈 글리카트 아게 | 이중특이적 항-vegf/항-ang-2 항체 및 안 혈관 질환의 치료에 있어서 이의 용도 |
PL2880167T3 (pl) | 2012-07-31 | 2018-12-31 | The Board Of Regents Of The University Of Texas System | Sposoby i kompozycje do indukcji tworzenia trzustkowych komórek beta in vivo |
AU2013328782C1 (en) | 2012-10-11 | 2018-01-18 | Ascendis Pharma Ophthalmology Division A/S | VEGF neutralizing prodrugs for the treatment of ocular conditions |
WO2014074823A1 (en) | 2012-11-08 | 2014-05-15 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
EP2922572A1 (en) | 2012-11-23 | 2015-09-30 | AB Science | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections |
GB2549865B (en) * | 2013-03-15 | 2018-01-17 | Aerpio Therapeutics Inc | Formulations comprising a compound that activates Tie-2 and their use in treating ocular diseases |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
CA2909080C (en) | 2013-04-11 | 2022-07-26 | Sunnybrook Research Institute | Methods, uses and compositions of tie2 agonists |
WO2014203182A1 (en) | 2013-06-20 | 2014-12-24 | Novartis Ag | Use of a vegf antagonist in treating choroidal neovascularisation |
EP3010526A1 (en) | 2013-06-20 | 2016-04-27 | Novartis AG | Use of a vegf antagonist in treating macular edema |
WO2015002893A1 (en) | 2013-07-02 | 2015-01-08 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
KR20160029794A (ko) | 2013-07-11 | 2016-03-15 | 노파르티스 아게 | 소아 환자의 맥락망막 신생혈관성 및 투과성 장애의 치료에 있어서 vegf 길항제의 용도 |
KR20160030504A (ko) | 2013-07-11 | 2016-03-18 | 노파르티스 아게 | 미숙아 망막병증의 치료에 있어서 vegf 길항제의 용도 |
US9828422B2 (en) | 2013-07-29 | 2017-11-28 | Samsung Electronics Co., Ltd. | Anti-Ang2 antibody |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
ES2731531T3 (es) | 2013-10-01 | 2019-11-15 | Sphingotec Gmbh | Método para predecir el riesgo de experimentar un episodio cardiaco adverso grave |
LT3062811T (lt) | 2013-11-01 | 2019-05-10 | Regeneron Pharmaceuticals, Inc. | Intervencijos angiopoietino pagrindu cerebrinės maliarijos gydymui |
JP6483148B2 (ja) | 2014-03-14 | 2019-03-13 | エアーピオ セラピューティクス インコーポレイテッド | HPTP−β阻害剤 |
WO2015152416A1 (ja) * | 2014-04-04 | 2015-10-08 | 国立大学法人東北大学 | 眼圧降下剤 |
CN106163946B (zh) | 2014-04-04 | 2018-12-21 | 株式会社大造 | 排出容器 |
US9719135B2 (en) | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
US20160082129A1 (en) | 2014-09-24 | 2016-03-24 | Aerpio Therapeutics, Inc. | VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector |
TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
JP6959924B2 (ja) | 2015-09-23 | 2021-11-05 | エアーピオ ファーマシューティカルズ, インコーポレイテッド | Tie−2の活性化物質を用いる眼内圧を処置する方法 |
CA3138682A1 (en) * | 2019-04-29 | 2020-11-05 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
-
2016
- 2016-09-22 JP JP2018534502A patent/JP6959924B2/ja active Active
- 2016-09-22 AU AU2016326510A patent/AU2016326510B2/en active Active
- 2016-09-22 EP EP21191499.9A patent/EP3977994B1/en active Active
- 2016-09-22 WO PCT/US2016/053107 patent/WO2017053566A1/en active Application Filing
- 2016-09-22 CN CN201680068508.2A patent/CN108290057A/zh active Pending
- 2016-09-22 CN CN202110932276.3A patent/CN113713101B/zh active Active
- 2016-09-22 MY MYPI2018000423A patent/MY194736A/en unknown
- 2016-09-22 KR KR1020187010228A patent/KR20180054677A/ko not_active Application Discontinuation
- 2016-09-22 ES ES16849594T patent/ES2894802T3/es active Active
- 2016-09-22 EP EP16849594.3A patent/EP3352856B1/en active Active
- 2016-09-22 BR BR112018005499A patent/BR112018005499A2/pt not_active Application Discontinuation
- 2016-09-22 MX MX2018003542A patent/MX2018003542A/es unknown
- 2016-09-22 CA CA2998673A patent/CA2998673C/en active Active
- 2016-09-22 US US15/273,068 patent/US10952992B2/en active Active
- 2016-09-22 SG SG10201912000WA patent/SG10201912000WA/en unknown
-
2018
- 2018-03-15 IL IL258150A patent/IL258150B/en active IP Right Grant
- 2018-03-22 MX MX2021010915A patent/MX2021010915A/es unknown
- 2018-03-23 PH PH12018500658A patent/PH12018500658A1/en unknown
-
2021
- 2021-01-15 US US17/150,430 patent/US11666558B2/en active Active
- 2021-10-08 JP JP2021165943A patent/JP7451472B2/ja active Active
-
2022
- 2022-04-20 AU AU2022202618A patent/AU2022202618B2/en active Active
-
2023
- 2023-04-21 US US18/304,511 patent/US20230398100A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018005499A2 (pt) | métodos de tratamento de pressão intraocular com ativadores de tie-2. | |
BR112018005409A2 (pt) | terapêutica de glicodirecionamento. | |
DK3341479T3 (da) | LNA-G-Proces | |
CL2014003447S1 (es) | Refrigerador. | |
BR112016018754A2 (pt) | método de tratamento de um câncer com vascularização | |
BR112018000204A2 (pt) | métodos de tratamento de colite | |
DK3262182T3 (da) | Modificeret creatinase | |
BR112016019822A2 (pt) | Determinação enzimática de hba1c | |
DE112017005876A5 (de) | CVT-Antriebsstrang | |
DE112015001600A5 (de) | CVT-Antriebsstrang | |
DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
DK3445722T3 (da) | Pef-kammer | |
MA45420A (fr) | Traitements combinés avec seribantumab | |
BR112017004526A2 (pt) | roldana de duto pressurizado | |
DE112016005703A5 (de) | Stufenlosgetriebe | |
ES1149884Y (es) | Calzado luminoso | |
ES2661264T8 (es) | Tratamiento de superficies curvadas | |
FI20140362A (fi) | Fotoniavusteinen pinnan pinnoitusmenetelmä | |
FI20145173L (fi) | Esikammiojärjestely | |
DE112017003989A5 (de) | CVT-Antriebsstrang | |
FR3021742B1 (fr) | Veine instrumentee de turbomachine | |
DE112017002208A5 (de) | Stufenlosgetriebe | |
FI20155772A (fi) | Menetelmä biolietteen käsittelemiseksi | |
TH176299B (th) | วิธีการบำบัดทางชีวภาพและชุดเครื่องบำบัดทางชีวภาพ | |
DK3154354T3 (da) | Styret pølsefremstillingsproces |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |